» Articles » PMID: 24919418

Effects of Upregulated Indoleamine 2, 3-dioxygenase 1 by Interferon γ Gene Transfer on Interferon γ-mediated Antitumor Activity

Overview
Journal Gene Ther
Date 2014 Jun 13
PMID 24919418
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Interferon γ (IFN-γ), an anticancer agent, is a strong inducer of indoleamine 2,3-dioxygenase 1 (IDO1), which is a tryptophan-metabolizing enzyme involved in the induction of tumor immune tolerance. In this study, we investigated the IDO1 expression in organs after IFN-γ gene transfer to mice. IFN-γ gene transfer greatly increased the mRNA expression of IDO1 in many tissues with the highest in the liver. This upregulation was associated with reduced L-tryptophan levels and increased L-kynurenine levels in serum, indicating that IFN-γ gene transfer increased the IDO activity. Then, Lewis lung carcinoma (LLC) tumor-bearing wild-type and IDO1-knockout (IDO1 KO) mice were used to investigate the effects of IDO1 on the antitumor activity of IFN-γ. IFN-γ gene transfer significantly retarded the tumor growth in both strains without any significant difference in tumor size between the two groups. By contrast, the IDO1 activity was increased only in the wild-type mice by IFN-γ gene transfer, suggesting that cells other than LLC cells, such as tumor stromal cells, are the major contributors of IDO1 expression in LLC tumor. Taken together, these results imply that IFN-γ gene transfer mediated IDO1 upregulation in cells other than LLC cells has hardly any effect on the antitumor activity of IFN-γ.

Citing Articles

Role of the SOX family in cancer immune evasion: Emerging player and promising therapeutic opportunities.

Li J, Xu Y, Han Y, Yang A, Qian M, Wang B Medicine (Baltimore). 2025; 104(5):e41393.

PMID: 39889187 PMC: 11789896. DOI: 10.1097/MD.0000000000041393.


Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.

Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.

PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.


Recent Advances of RNA mA Modifications in Cancer Immunoediting and Immunotherapy.

Ma S, Barr T, Yu J Cancer Treat Res. 2023; 190:49-94.

PMID: 38112999 DOI: 10.1007/978-3-031-45654-1_3.


L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes.

Schlichtner S, Yasinska I, Klenova E, Abooali M, Lall G, Berger S Oncoimmunology. 2023; 12(1):2244330.

PMID: 37577144 PMC: 10416736. DOI: 10.1080/2162402X.2023.2244330.


Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1.

Tayshetye P, Friday A, Omstead A, Verma T, Miller S, Zheng P Cancers (Basel). 2023; 15(1).

PMID: 36612271 PMC: 9818440. DOI: 10.3390/cancers15010276.